Project Grant R21CA299766
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$216K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The funding will support the development and testing of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of disease subtypes using a proprietary class of small RNAs called orphan non-coding RNAs (OncRNAs). This...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop noninvasive imaging and blood-based biomarkers to improve prediction of immunotherapy response and clinical benefit for patients with advanced non-small cell lung cancer (NSCLC).
The $627,705 award to The Leland Stanford Junior University will fund research to: (1) develop knowledge-guided radiomics and deep learning models to enhance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by the principal investigator at the University of Texas MD Anderson Cancer Center to evaluate the use of liquid biopsy techniques, including circulating tumor DNA (ctDNA) and extracellular RNA (exRNA), to assess patient outcomes and treatment response in clinical trials for colorectal and anal cancers. The $181,640 award, effective September 12, 2024 through...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This National Cancer Institute (NCI) Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" program aims to develop a prognostic assay to predict metastatic progression in clear cell renal cell carcinoma (cCRCC). The $927,997 award to Lagrange Scientific LLC, a small disadvantaged business, supports the expansion of a prototype metabolite-based biomarker panel that demonstrated 100% specificity and 83% sensitivity in pilot studies for identifying cCRCC patients at...
This three-year, $1.335 million Project Grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), will support biomarkers research of response to combination cabozantinib and nivolumab treatment in advanced renal cell carcinoma. The grantee, Dana-Farber Cancer Institute, will analyze whole exome sequencing, RNA sequencing, and clinical outcome data to identify genetic alterations and gene expression signatures that impact...
This $330,942 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a 5-year research project at Stanford University to study the variability in how engineered T cell immunotherapies perform across different cancer patients. The project aims to develop scalable screening methodologies to rapidly assess the function of various chimeric antigen receptor (CAR) T cell constructs across large patient cohorts, dissect the intrinsic...
This $755,970 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research will fund research to address key challenges in the diagnosis and treatment of immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN). The primary objectives are to:
Determine the accuracy of urine CXCL9 as a biomarker to distinguish ICI-AIN from other causes of acute kidney...
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...